Drug intelligence / Profile preview

fluoro-donepezil

Development stage: Unknown
Lead developer: Lianyungang Kanion
Modality: Small Molecules
Administration: Oral

Overview

Fluoro-donepezil (also known as KNP01) is a small molecule acetylcholinesterase inhibitor (AChEI) developed by Jiangsu Kanion Pharmaceutical for the treatment of Alzheimer's disease. It is a fluorinated derivative of donepezil, a standard-of-care treatment for Alzheimer's. The incorporation of fluorine atoms into the donepezil scaffold is intended to optimize the drug's pharmacokinetic properties, potentially improving metabolic stability and brain permeability. Clinical development has progressed through Phase 1 trials in China, where it was evaluated for safety, tolerability, and pharmacokinetics in healthy elderly volunteers.

Other names: fluoro-donepezilfluorodonepezil氟多奈哌齐

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on fluoro-donepezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoro-donepezil.

Explore the full profile